CN103930414B - 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体 - Google Patents

7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体 Download PDF

Info

Publication number
CN103930414B
CN103930414B CN201280055120.0A CN201280055120A CN103930414B CN 103930414 B CN103930414 B CN 103930414B CN 201280055120 A CN201280055120 A CN 201280055120A CN 103930414 B CN103930414 B CN 103930414B
Authority
CN
China
Prior art keywords
crystal
crystals
methyl
fluoroethyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280055120.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103930414A (zh
Inventor
荒谷一郎
后藤晃范
皆川渡
船田惠子
长尾宗树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinglin Pharmaceutical Holdings Co ltd
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103930414(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to CN201510329284.3A priority Critical patent/CN104945375B/zh
Publication of CN103930414A publication Critical patent/CN103930414A/zh
Application granted granted Critical
Publication of CN103930414B publication Critical patent/CN103930414B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201280055120.0A 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体 Active CN103930414B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510329284.3A CN104945375B (zh) 2011-11-10 2012-11-09 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2011-246209 2011-11-10
JP2012071739 2012-03-27
JP2012-071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 ７－｛（３s、４s）－３－［（シクロプロピルアミノ)メチル］－４－フルオロピロリジン－1－イル｝－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１、４－ジヒドロキノリン－３－カルボン酸の結晶

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510329284.3A Division CN104945375B (zh) 2011-11-10 2012-11-09 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体

Publications (2)

Publication Number Publication Date
CN103930414A CN103930414A (zh) 2014-07-16
CN103930414B true CN103930414B (zh) 2016-01-20

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280055120.0A Active CN103930414B (zh) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体
CN201510329284.3A Active CN104945375B (zh) 2011-11-10 2012-11-09 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510329284.3A Active CN104945375B (zh) 2011-11-10 2012-11-09 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP3112359B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR102162208B1 (enExample)
CN (2) CN103930414B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2621664T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2017109814A (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG10201608167UA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2014174848A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 錠剤
ES2768651T3 (es) 2013-04-25 2020-06-23 Kyorin Seiyaku Kk Composición farmacéutica sólida
EP2990039A4 (en) * 2013-04-25 2017-02-22 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA2965473A1 (en) * 2014-10-23 2016-04-28 Kyorin-Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6832706B2 (ja) * 2014-10-23 2021-02-24 杏林製薬株式会社 固形医薬組成物
CN113975277B (zh) * 2015-03-13 2024-10-18 杏林制药株式会社 呼吸器官感染治疗剂
WO2016195021A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
WO2016195020A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
CA2987879A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2018230686A1 (ja) 2017-06-16 2018-12-20 杏林製薬株式会社 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤
JP6618660B2 (ja) 2017-06-16 2019-12-11 杏林製薬株式会社 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849316A (zh) * 2003-09-10 2006-10-18 杏林制药株式会社 7－(4－取代－3－环丙基氨基甲基－1－吡咯烷基)喹诺酮羧酸衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030118078A1 (en) * 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003076428A1 (en) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849316A (zh) * 2003-09-10 2006-10-18 杏林制药株式会社 7－(4－取代－3－环丙基氨基甲基－1－吡咯烷基)喹诺酮羧酸衍生物

Also Published As

Publication number Publication date
BR112014010765A2 (pt) 2017-06-13
NZ623808A (en) 2015-07-31
AU2012337206A1 (en) 2014-05-22
US9328089B2 (en) 2016-05-03
CN104945375A (zh) 2015-09-30
EP3112359B1 (en) 2019-08-21
CN103930414A (zh) 2014-07-16
KR20140098074A (ko) 2014-08-07
MX375073B (es) 2025-03-06
JP2017160243A (ja) 2017-09-14
EP2778159B1 (en) 2017-03-01
US20140288310A1 (en) 2014-09-25
AU2016273899B2 (en) 2017-07-27
SG11201401817TA (en) 2014-08-28
US9090587B2 (en) 2015-07-28
EP3112359A1 (en) 2017-01-04
EP2778159A1 (en) 2014-09-17
EP2778159A4 (en) 2015-06-03
CA2855022C (en) 2019-05-07
RU2615509C2 (ru) 2017-04-05
JP2018158949A (ja) 2018-10-11
JP5871948B2 (ja) 2016-03-01
IN2014DN03277A (enExample) 2015-05-22
SG10201608167UA (en) 2016-11-29
RU2014123567A (ru) 2015-12-20
WO2013069297A1 (ja) 2013-05-16
TW201332991A (zh) 2013-08-16
BR112014010765B1 (pt) 2020-07-14
AU2016273899A1 (en) 2017-01-12
ES2621664T3 (es) 2017-07-04
JP2016027045A (ja) 2016-02-18
JP6818719B2 (ja) 2021-01-20
AU2012337206A8 (en) 2016-09-22
CN104945375B (zh) 2017-07-04
TWI547492B (zh) 2016-09-01
SA112330992B1 (ar) 2015-09-13
JPWO2013069297A1 (ja) 2015-04-02
CA2855022A1 (en) 2013-05-16
ES2747303T3 (es) 2020-03-10
AU2012337206B2 (en) 2016-09-15
JP6349435B2 (ja) 2018-06-27
US20150284361A1 (en) 2015-10-08
KR102162208B1 (ko) 2020-10-06
RU2017109814A (ru) 2019-01-23
RU2017109814A3 (enExample) 2020-04-08
KR20190065456A (ko) 2019-06-11
JP6514069B2 (ja) 2019-05-15
USRE47785E1 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
CN103930414B (zh) 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体
CN114728899A (zh) 新型三苯基化合物盐
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CA2965716A1 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
AU2012337206B8 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
MX2014005007A (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
EP3710425A1 (en) Solid state forms of elafibranor
WO2018054359A1 (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
HK1210080A1 (en) Sulfate of 5-hydroxy-1h-imidazole-4-carboxamide
EP3052499A1 (en) Crystalline abacavir hydrochloride monohydrate and process for its preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region after: Japan

Address before: Tokyo, Japan

Patentee before: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region before: Japan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240301

Address after: Tokyo, Japan

Patentee after: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region after: Japan

Address before: Tokyo, Japan

Patentee before: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan